BRPI0718850A2 - METHODS OF TREATING, DIAGNOSING OR DETECTION CANCER - Google Patents

METHODS OF TREATING, DIAGNOSING OR DETECTION CANCER

Info

Publication number
BRPI0718850A2
BRPI0718850A2 BRPI0718850-1A2A BRPI0718850A BRPI0718850A2 BR PI0718850 A2 BRPI0718850 A2 BR PI0718850A2 BR PI0718850 A BRPI0718850 A BR PI0718850A BR PI0718850 A2 BRPI0718850 A2 BR PI0718850A2
Authority
BR
Brazil
Prior art keywords
diagnosing
treating
methods
detection cancer
cancer
Prior art date
Application number
BRPI0718850-1A2A
Other languages
Portuguese (pt)
Inventor
Albert Lai
Guoying K Yu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0718850A2 publication Critical patent/BRPI0718850A2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
BRPI0718850-1A2A 2006-11-14 2007-11-09 METHODS OF TREATING, DIAGNOSING OR DETECTION CANCER BRPI0718850A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85888206P 2006-11-14 2006-11-14
PCT/US2007/084293 WO2008061020A2 (en) 2006-11-14 2007-11-09 Methods of treating, diagnosing or detecting cancer

Publications (1)

Publication Number Publication Date
BRPI0718850A2 true BRPI0718850A2 (en) 2014-02-25

Family

ID=39402414

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718850-1A2A BRPI0718850A2 (en) 2006-11-14 2007-11-09 METHODS OF TREATING, DIAGNOSING OR DETECTION CANCER

Country Status (9)

Country Link
EP (1) EP2084540A2 (en)
JP (1) JP2010509368A (en)
KR (1) KR20090080082A (en)
CN (1) CN101558308A (en)
AU (1) AU2007319360A1 (en)
BR (1) BRPI0718850A2 (en)
CA (1) CA2668714A1 (en)
MX (1) MX2009005058A (en)
WO (1) WO2008061020A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
RS54215B1 (en) 2005-10-31 2015-12-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
JP2013530929A (en) 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド Frizzled binders and uses thereof
EP2694963B1 (en) 2011-04-01 2017-08-02 Qiagen Gene expression signature for wnt/b-catenin signaling pathway and use thereof
JP5944994B2 (en) * 2011-08-12 2016-07-05 オメロス コーポレーション Anti-FZD10 monoclonal antibodies and methods for their use
JP6155255B2 (en) * 2012-04-17 2017-06-28 Hoya株式会社 FZD10 binding peptide
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
CN103048446B (en) * 2012-12-25 2015-02-04 苏州浩欧博生物医药有限公司 Luteinizing hormone nano-magnetic particle chemiluminescence assay kit and preparation method thereof and assay method thereof
EP2950885B1 (en) 2013-02-04 2018-11-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP2997378B1 (en) * 2013-05-16 2018-08-08 Kyoto University Method for determining prognosis of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020668A2 (en) * 2002-08-30 2004-03-11 Oncotherapy Science, Inc. Method for treating synovial sarcoma
ES2381841T3 (en) * 2003-07-11 2012-06-01 Oncotherapy Science, Inc. Method to treat synovial sarcoma
EP2044123B1 (en) * 2006-06-21 2013-03-13 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to fzd10 and uses thereof

Also Published As

Publication number Publication date
MX2009005058A (en) 2009-05-25
EP2084540A2 (en) 2009-08-05
AU2007319360A1 (en) 2008-05-22
KR20090080082A (en) 2009-07-23
WO2008061020A3 (en) 2008-08-07
CA2668714A1 (en) 2008-05-22
WO2008061020A9 (en) 2008-11-13
WO2008061020A2 (en) 2008-05-22
CN101558308A (en) 2009-10-14
JP2010509368A (en) 2010-03-25

Similar Documents

Publication Publication Date Title
BRPI0718850A2 (en) METHODS OF TREATING, DIAGNOSING OR DETECTION CANCER
BRPI0809137A2 (en) methods of diagnosing, endometrial cancer and precancer classify and treat
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
CR10667A (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
WO2010017515A3 (en) Breast cancer specific markers and methods of use
BRPI0815588A2 (en) POLYORGANOSYLOXAN-POLYURERIA AND / OR POLYORGANOSYL-XANO-POLYURETHANE COMPOUNDS
BRPI0920104A2 (en) solution or wastewater treatment
BRPI0719202A2 (en) Diagnosis and treatment of cancer using antiereg antibody
BRPI0715763A2 (en) treating or preventing cancers by overexpressing reg4 or kiaa0101
BRPI0717082A2 (en) HYDROCARBON GAS PROCESSING
BRPI0814307A2 (en) PRESBIOPIC TREATMENT SYSTEM
BRPI0813364A2 (en) DIAGNOSTIC METHODS AND CANCER TREATMENT.
ES2322882B1 (en) INHIBITING PEPTIDES OF NEURONAL EXOCITOSIS.
BRPI0811775A2 (en) POLYCARBONATE COMPOUNDS-AND / OR POLYURETHANE-POLYORGANOSILOXANE
BRPI0817779A2 (en) Hydrocarbon Gas Processing
BRPI0921122A2 (en) prostate therapy system.
BRPI0921422A2 (en) prostate therapy system.
BRPI0906975A2 (en) Toothbrush for the treatment and / or detection of microbes.
EP2147124A4 (en) Epigenetic biomarkers for early detection, therapeutic effectiveness, and relapse monitoring of cancer
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
BRPI0814849A2 (en) COMPACT WASH GUT SYSTEM
BRPI0917321A2 (en) prevention, treatment and diagnosis of p. gingivalis
BRPI0813681A2 (en) DETECTION OF NEMATELMINTH COPROANTIGEN
EP2016172A4 (en) Diagnostic methods for determining treatment
BRPI0822002A2 (en) treatment of colon disease or prevention of colorectal carcinoma with imidazoquinoline derivatives.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired